Pfizer and its partner BioNTech just launched the first human trials of their revised COVID vaccine which has been adapted to try and provide better protection against the omicron variant.
Shortly after the emergence of omicron in late November, Pfizer and its rivals all promised to produce another generation of vaccines, claiming they could have them ready within three months.
An even more important question for Pfizer might be this: who will even need these jabs when they're ready, since it looks like the omicron wave numbers will have finally tapered off by the time the trials are completed.
The trials will seek to examine the safety, tolerability and, most importantly, the immune response generated by the new vaccines, per WSJ. The big question will be whether they do what their makers have created them to do, or not.
At least one human subject has already received a shot of the new vaccine, Pfizer said Tuesday.
US health authorities have said that boosters targeting omicron might not be needed, since it's unclear whether future dominant variants will be descents of omicron, or other strains.
As for the new trials, the two firms said they would test how the vaccine performs in three groups of volunteers, with some of the subjects coming from the study that led to the current vaccine's clearance in 2020.
https://www.zerohedge.com/covid-19/pfizer-launches-trials-new-omicron-vaccine-cases-continue-slump
No comments:
Post a Comment